Starpharma

DR JACKIE FAIRLEY

CEO

STARPHARMA HOLDINGS

(ASX:SPL)

◾ Company Name: Starpharma Holdings ◾ Company ASX code: SPL ◾ Key areas: Health and medical products and pharmaceuticals ◾ Key Personnel: Mr Robert Thomas, Non-Executive Chairman | Dr Jackie Fairley, CEO | Mr Nigel Baade, CFO and Company Secretary ◾ Locations: Melbourne, Australia ◾ Market Cap as of 15/09/22: $236.80M ◾ 52 Week share price as of 15 September: $0.550 - $1.495 ◾ Company Website: starpharma.com

COMPANY PROFILE

Starpharma is an Australian biotechnology company focused on the development and commercialisation of medical products and pharmaceuticals based on its proprietary dendrimer technology.

The company has developed its core range of innovative products around highly branched nanoscale polymers called dendrimers, whose precise size and unique structural properties make them perfect for use in pharmaceutical and medical applications.

Starpharma’s dendrimer technology plays a starring role in its marketed products, VIRALEZE™ nasal spray and VivaGel®, but SPL’s “holy grail” is a range of dendrimer-delivered anti-cancer therapies aimed at providing improved efficacy and reduced toxic side effects for novel or existing drugs.

This dendrimer-enhanced product (DEP®) technology is highly promising in its potential to offer multiple commercial and therapeutic benefits.

Commercially, Starpharma is seeking to attract development and market partnerships, leveraging the flexibility of DEP® technology in a wide range of therapeutic areas, and how this opens up multiple revenue streams and potential for new intellectual property and patent extensions.

Starpharma has already secured partnerships with several of the world’s largest pharmaceutical companies, including a multiproduct licence with AstraZeneca and research collaborations with Merck & Co., Inc., and Genentech.

On the therapeutic side, the potential upsides are enormous in terms of patient comfort and medical outcomes, particularly considering the role Starpharma sees DEP® technology playing in enhancing the efficacy and reducing the toxic side effects of conventional cancer treatments.

Because of the scale of the technology, Starpharma says it also has potential to help target the delivery of other drugs to organs, tissues or molecular receptors, with enhanced solubility.

Starpharma has developed four clinical stage dendrimer-based oncology drugs to aid in the fight against cancer. Three of the drugs are in Phase 2 clinical trials for the treatment of a range of cancers, including prostate, ovarian, pancreatic, colorectal, and oesophageal, with a fourth expected to enter the clinic later in CY2022.

Additionally, SPL has brought three products to market, built using its patented dendrimer, SPL7013, originally identified for its antiviral activity against sexually transmitted viral infections, including HIV, HPV, and genital herpes.

The products developed using SPL7013 are VIRALEZE™ nasal spray, VivaGel® BV, and VivaGel® condom.

VIRALEZE™ is a broad-spectrum nasal spray developed in response to the Covid-19 outbreak in 2020, to trap and block respiratory viruses in the nasal cavity.

Extensive testing at the renowned Scripps Research institute in the United States has clearly demonstrated strong antiviral effects of SPL7013 against multiple viruses, including multiple variants of SARS-CoV-2 and influenza, as well as RSV, MERS, SARS.

Starpharma has worked tirelessly to get VIRALEZE™ registered in more than 30 countries, and today it is available from a variety of retail outlets and pharmacies around the world, as well as online.

VivaGel® BV is a novel, non-antibiotic gel containing SPL7013 for the treatment of bacterial vaginosis (BV) and the prevention of recurrent BV.

Throughout the world, BV is the most common vaginal infection. It is caused by an imbalance of healthy and harmful bacteria in the vagina, and can lead to abnormal vaginal discharge and odour that are unpleasant and can interfere with a woman’s relationships and general quality of life.

VivaGel® BV is registered in more than 45 countries.

KEY INVESTMENT HIGHLIGHTS

JULY 20, 2022: Study finds VIRALEZE™ offers high protection against the SARS-CoV-2 Omicron variant. AUGUST 10, 2022: Starpharma sign a new DEP® agreement with Merck, USA. SEPTEMBER 12, 2022: Interim trial results presented at ESMO show efficacy signals in 100% of prostate cancer patients assessed following DEP® cabazitaxel treatment.